VFA
MRNS

Virtus Fund Advisers’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Virtus Fund Advisers’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$308K Buy
+9,451
New +$255K ﹤0.01% 448

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtus Fund Advisers's MRNS Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Marinus Pharmaceuticals, Inc (MRNS) in Q4 2017: 9,451 shares worth $308K. The stake represents ﹤0.01% of the portfolio and ranks #448 among its holdings.

65 funds tracked by Wall St. Rank hold MRNS as of Q4 2017.

  • Virtus Fund Advisers held 9,451 shares of Marinus Pharmaceuticals, Inc worth $308K as of Q4 2017.
  • Marinus Pharmaceuticals, Inc was a new Virtus Fund Advisers position in Q4 2017.
  • Marinus Pharmaceuticals, Inc made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #448 holding.
  • 65 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.